News
Company News: Curetis’ Global Installed Base Expanding to Over 150 Unyvero Analyzers
– Completion of EMEA Direct Sales team build-out drives 46% growth in system installations over the course of 2016
– Reported unaudited FY 2016 revenue and strong year-end cash position
Curetis N.V. (Euronext: CURE, the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced the installation of its milestone 150th Unyvero Analyzer worldwide.
Company News: Anergis Appoints Klaus Schollmeier as New Chairman of the Board of Directors
– Senior Pharma and Biotech Executive joins Anergis´ Board of Directors as New Chairman
Anergis SA, a Swiss clinical-stage biopharmaceutical company developing proprietary products for ultra-fast allergy immunotherapy, today announced the appointment of Dr. Klaus Schollmeier as Chairman of its Board of Directors.
Company News: Phenex receives 100 M USD Milestone Payment from Gilead
Phenex Pharmaceuticals AG (Phenex) today announced that the company has received a 100 M USD milestone payment from Gilead Sciences, Inc. of Foster City, CA, U.S.A., for its program with GS-9674 targeting nonalcoholic steatohepatitis (NASH). GS-9674 is a novel, synthetic and non-steroidal FXR agonist which was originally developed by Phenex and then sold to Gilead. In December 2014, Gilead acquired the Farnesoid X Receptor (FXR) program from Phenex, in a deal valued at 470 million USD. GS-9674 is the clinical drug candidate that Gilead has elected to test in patients with liver diseases such as NASH, primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC).
Company News: Curetis Files for U.S. FDA Clearance for Unyvero Platform and LRT Application Cartridge
– Final panel demonstrates overall weighted average sensitivity of 91.4% and overall weighted average specificity of 99.5% across all lower respiratory tract panel pathogens
– Unyvero results available after approximately five hours only, compared to three to four days on average for microbiology culture based methods
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration for its Unyvero Platform and the Unyvero LRT Lower Respiratory Tract Cartridge.